Berlin Pharmaceutical Industry Co., Ltd. and Acino Pharma signed a long term partnership agreement under which Berlin will market a wide range of the Swiss company's current and future products in Thailand.
“The new products will complement our current line of therapies as well as significantly expand our presence into new areas,” said Amal Naj, chief executive officer of Berlin. “We are very excited about this association with Acino and the high quality products we will bring to our patients at affordable prices,” he said.
Peter Burema, CEO of Acino Group, said, “We are very pleased to partner with one of the leading pharmaceutical companies in Thailand to introduce our products in the market. We see great opportunities for our products there and rest of Asia and other emerging markets.”
Acino specializes in the development, registration and manufacture of generic and innovative pharmaceuticals using advanced drug delivery technologies, for which it also holds patents. With a focus on solid oral dosage forms with modified release of the active ingredient, transdermal therapeutic patches and biodegradable, subcutaneous implants, Acino supplies leading pharmaceutical companies throughout Europe.
Naj said the vast majority of the Acino products Berlin will introduce in Thailand are for the treatment of urological disorders, cancer and pain. The company's current products are prescribed mainly for the treatment of cardiovascular and metabolic diseases and gastro-intestinal disorders. Naj said a number of Acino products are innovative, and they will help strengthen Berlin's market presence in the highly competitive market.
Berlin currently manufactures most of its products in GMP-approved (Good Manufacturing Practice) and ISO-certified facilities, and imports Active Pharmaceutical Ingredients (API) as well as finished products from Canada, France, and India.